Citation Impact
Citing Papers
DiarrheagenicEscherichia coli
1998 Standout
Treatment With the Radiolabeled Somatostatin Analog [ 177 Lu-DOTA 0 ,Tyr 3 ]Octreotate: Toxicity, Efficacy, and Survival
2008
Placebo-Controlled, Double-Blind, Prospective, Randomized Study on the Effect of Octreotide LAR in the Control of Tumor Growth in Patients With Metastatic Neuroendocrine Midgut Tumors: A Report From the PROMID Study Group
2009 Standout
Effect of Fluid Resuscitation with and without Endothelin A Receptor Blockade on Hemoconcentration and Organ Function in Experimental Pancreatitis
2000
A randomised, double blind, multicentre trial of octreotide in moderate to severe acute pancreatitis
1999
Somatostatin analogue octreotide and inhibition of tumour growth in metastatic endocrine gastroenteropancreatic tumours.
1996
Double blind, randomised, placebo controlled study of a platelet activating factor antagonist, lexipafant, in the treatment and prevention of organ failure in predicted severe acute pancreatitis
2001
Direct and Catalytic C ‐Glycosylation of Arenes: Expeditious Synthesis of the Remdesivir Nucleoside**
2021 StandoutNobel
Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes
2023 Standout
Characterization of Bradykinin-Related Peptides Generated in the Plasma of Six Sarcopterygian Species (African Lungfish, Amphiuma, Coachwhip, Bullsnake, Gila Monster, and Gray's Monitor)
1998
Prospective placebo-controlled randomized trial of lexipafant in predicted severe acute pancreatitis
1997
Glucagon-like peptide 1 and its derivatives in the treatment of diabetes
2004
Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes
2016 Standout
Factors Predicting Mortality in Severe Acute Pancreatitis
2003
Pathogenesis of type 2 diabetes mellitus
2004
Classification of acute pancreatitis—2012: revision of the Atlanta classification and definitions by international consensus
2012 Standout
Predicting fatal outcome in the early phase of severe acute pancreatitis by using novel prognostic models
2003
Effects of enprostil on gastric endocrine secretion during chronic administration of lansoprazole
1997
Everolimus for Advanced Pancreatic Neuroendocrine Tumors
2011 Standout
Intestinal Electrolyte Transport and Diarrheal Disease
1989
Characterization of the Carboxyl-terminal Domain of the Rat Glucose-dependent Insulinotropic Polypeptide (GIP) Receptor
1999
Microbial tryptophan catabolites in health and disease
2018 Standout
Cystic fibrosis
2016 Standout
Postprandial stimulation of insulin release by glucose-dependent insulinotropic polypeptide (GIP). Effect of a specific glucose-dependent insulinotropic polypeptide receptor antagonist in the rat.
1996
Mechanisms by which common variants in the TCF7L2 gene increase risk of type 2 diabetes
2007
Four weeks of near-normalisation of blood glucose improves the insulin response to glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide in patients with type 2 diabetes
2008
Acute Pancreatitis: Does Gender Matter?
2001
Guidelines for the management of acute pancreatitis
2002
Hemoconcentration Is an Early Marker for Organ Failure and Necrotizing Pancreatitis
2000
Synthesis and Properties of Allenic Natural Products and Pharmaceuticals
2004 Standout
Physiology and immunology of the cholinergic antiinflammatory pathway
2007 Standout
Role of incretin hormones in the regulation of insulin secretion in diabetic and nondiabetic humans
2004
Severe Acute Pancreatitis: When to Be Concerned?
2003
Nanoferroelectrics: statics and dynamics
2006
Review of the usefulness of contacting other experts when conducting a literature search for systematic reviews
1998
The gut–renal axis: do incretin-based agents confer renoprotection in diabetes?
2013
Lixisenatide in Patients with Type 2 Diabetes and Acute Coronary Syndrome
2015 Standout
Treatment of neuroendocrine tumors
1994
Cardiovascular effects of Glucagon-like peptide 1 (GLP-1) receptor agonists
2014
Sunitinib Malate for the Treatment of Pancreatic Neuroendocrine Tumors
2011 Standout
GLUCAGON-LIKE PEPTIDE-1 7-36: A PHYSIOLOGICAL INCRETIN IN MAN
1987 Standout
THE POTENTIAL ROLE OF THERAPEUTIC CYTOKINE MANIPULATION IN ACUTE PANCREATITIS
1999
How May GIP Enhance the Therapeutic Efficacy of GLP-1?
2020
Endogenous glucagon-like peptide 1 controls endocrine pancreatic secretion and antro-pyloro-duodenal motility in humans
2005
Alcohol Consumption in Patients with Acute or Chronic Pancreatitis
2007
The elimination rates of intact GIP as well as its primary metabolite, GIP 3-42, are similar in type 2 diabetic patients and healthy subjects
2006
Dipeptidyl Peptidase IV Substrates
2004
Early Severe Acute Pancreatitis: Characteristics of a New Subgroup
2001
Fatal Outcome in Acute Pancreatitis: Its Occurrence and Early Prediction
2001
Acute Pancreatitis
2016 Standout
Does Mortality Occur Early or Late in Acute Pancreatitis?
2000
Similar Elimination Rates of Glucagon-Like Peptide-1 in Obese Type 2 Diabetic Patients and Healthy Subjects
2003
Cellular regulation of islet hormone secretion by the incretin hormone glucagon-like peptide 1
1998
Influence of Contrast-enhanced Computed Tomography on Course and Outcome in Patients with Acute Pancreatitis
2002
Blood glucose control in healthy subject and patients receiving intravenous glucose infusion or total parenteral nutrition using glucagon-like peptide 1
2004
Biology of Incretins: GLP-1 and GIP
2007 Standout
Carcinoid A Comprehensive Review
2003
Determinants of the Impaired Secretion of Glucagon-Like Peptide-1 in Type 2 Diabetic Patients
2001
Is obesity a risk factor in acute pancreatitis? A meta-analysis
2004
Immunoreactive Gastric Inhibitory Polypeptide*
1988
Isolation and cardiovascular activity of a second bradykinin-related peptide ([Arg0,Trp5,Leu8]bradykinin) from trout
1996
A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management
2015 Standout
The effects of glucose-dependent insulinotropic polypeptide infused at physiological concentrations in normal subjects and Type 2 (non-insulin-dependent) diabetic patients on glucose tolerance and B-cell secretion
1987
The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes
2006 Standout
Well-Differentiated Pancreatic Nonfunctioning Tumors/Carcinoma
2006
Near-normalisation of diurnal glucose concentrations by continuous administration of glucagon-like peptide-1 (GLP-1) in subjects with NIDDM
1997
Type 2 diabetes
2017 Standout
Glucagon-like peptide 1(GLP-1) in biology and pathology
2005
The path to ubiquitous and low-cost organic electronic appliances on plastic
2004 StandoutNature
Chemotherapy-Induced Nausea and Vomiting
2008 Standout
Bariatric Surgery versus Intensive Medical Therapy in Obese Patients with Diabetes
2012 Standout
THE METABOLIC IMPACT OF RAPAMYCIN (SIROLIMUS) IN CHRONIC CANINE ISLET GRAFT RECIPIENTS1
1996
A New Pathway for Glucose-dependent Insulinotropic Polypeptide (GIP) Receptor Signaling
2001
Human duodenal enteroendocrine cells: source of both incretin peptides, GLP-1 and GIP
2005
Obesity: A Risk Factor for Severe Acute Biliary and Alcoholic Pancreatitis
1998
Dipeptidyl peptidase 4 is a functional receptor for the emerging human coronavirus-EMC
2013 StandoutNature
Update on the treatment of neuroendocrine tumors
2003
Pancreatic proteases in serum induce leukocyte-endothelial adhesion and pancreatic microcirculatory failure
2005
Gluco-incretins control insulin secretion at multiple levels as revealed in mice lacking GLP-1 and GIP receptors
2004
Acute Pancreatitis
1994 Standout
Exenatide Augments First- and Second-Phase Insulin Secretion in Response to Intravenous Glucose in Subjects with Type 2 Diabetes
2005
Benefit of continuous regional arterial infusion of protease inhibitor and antibiotic in the management of acute necrotizing pancreatitis
2001
Preservation of active incretin hormones by inhibition of dipeptidyl peptidase IV suppresses meal-induced incretin secretion in dogs
2002
The safety and efficacy of liraglutide with or without oral antidiabetic drug therapy in type 2 diabetes: an overview of the LEAD 1–5 studies
2009
The Physiology of Glucagon-like Peptide 1
2007 Standout
ISLET CELL DAMAGE ASSOCIATED WITH TACROLIMUS AND CYCLOSPORINE: MORPHOLOGICAL FEATURES IN PANCREAS ALLOGRAFT BIOPSIES AND CLINICAL CORRELATION1
1999
Meta-analysis of Observational Studies in Epidemiology<SUBTITLE>A Proposal for Reporting</SUBTITLE>
2000 Standout
The Multifunctional Fish Gill: Dominant Site of Gas Exchange, Osmoregulation, Acid-Base Regulation, and Excretion of Nitrogenous Waste
2004 Standout
Purification of a vasoactive peptide related to lysyl‐bradykinin from trout plasma
1993
Islet Transplantation in Seven Patients with Type 1 Diabetes Mellitus Using a Glucocorticoid-Free Immunosuppressive Regimen
2000 Standout
Diagnosis, objective assessment of severity, and management of acute pancreatitis
1999
Reduction in Mortality With Delayed Surgical Therapy of Severe Pancreatitis
2002
Acute Necrotizing Pancreatitis: Treatment Strategy According to the Status of Infection
2000
Practice Guidelines in Acute Pancreatitis
2006 Standout
Bleeding Peptic Ulcer
1994 Standout
Laboratory Markers of Severe Acute Pancreatitis
2004
Is Severity of Necrotizing Pancreatitis Increased in Extended Necrosis and Infected Necrosis?
2002
Surgical management of severe pancreatitis including sterile necrosis.
2002
Secretion of incretin hormones and the insulinotropic effect of gastric inhibitory polypeptide in women with a history of gestational diabetes
2005
Saxagliptin and Cardiovascular Outcomes in Patients with Type 2 Diabetes Mellitus
2013 Standout
Cell and Molecular Biology of the Incretin Hormones Glucagon-Like Peptide-I and Glucose-Dependent Insulin Releasing Polypeptide
1995
Incretins, insulin secretion and Type 2 diabetes mellitus
2004
The Tachykinin Peptide Family
2002
Exenatide: first-in-class incretin mimetic for the treatment of Type 2 diabetes mellitus
2006
Prediabetes: a high-risk state for diabetes development
2012 Standout
Severe Acute Pancreatitis: Prognostic Factors in 270 Consecutive Patients
2000
Preserved incretin activity of glucagon-like peptide 1 [7-36 amide] but not of synthetic human gastric inhibitory polypeptide in patients with type-2 diabetes mellitus.
1993 Standout
Neuropeptide‐γ: A Peptide Isolated from Rabbit Intestine that Is Derived from γ‐Preprotachykinin
1988
Severe Acute Pancreatitis: Nonsurgical Treatment of Infected Necroses
2005
Dipeptidyl-Peptidase IV from Bench to Bedside: An Update on Structural Properties, Functions, and Clinical Aspects of the Enzyme DPP IV
2003
The incretin effect in healthy individuals and those with type 2 diabetes: physiology, pathophysiology, and response to therapeutic interventions
2016
Prospects of Colloidal Nanocrystals for Electronic and Optoelectronic Applications
2009 Standout
Fluorine in medicinal chemistry
2007 Standout
From the Triumvirate to the Ominous Octet: A New Paradigm for the Treatment of Type 2 Diabetes Mellitus
2009 Standout
Tirzepatide Once Weekly for the Treatment of Obesity
2022 Standout
Type 2 diabetes: principles of pathogenesis and therapy
2005 Standout
Defective Glucose-Dependent Insulinotropic Polypeptide Receptor Expression in Diabetic Fatty Zucker Rats
2001
Abolition by omeprazole of aspirin induced gastric mucosal injury in man.
1990
Double Incretin Receptor Knockout (DIRKO) Mice Reveal an Essential Role for the Enteroinsular Axis in Transducing the Glucoregulatory Actions of DPP-IV Inhibitors
2004
Prospective, Randomized, Multicenter Trial on the Antiproliferative Effect of Lanreotide, Interferon Alfa, and Their Combination for Therapy of Metastatic Neuroendocrine Gastroenteropancreatic Tumors—The International Lanreotide and Interferon Alfa Study Group
2003
Quantum-Dot Size and Thin-Film Dielectric Constant: Precision Measurement and Disparity with Simple Models
2014 StandoutNobel
Charge Carrier Transporting Molecular Materials and Their Applications in Devices
2007 Standout
New developments in the incretin concept
1985
Incretin hormones - an update
2001
Next Generation of Fluorine-Containing Pharmaceuticals, Compounds Currently in Phase II–III Clinical Trials of Major Pharmaceutical Companies: New Structural Trends and Therapeutic Areas
2016 Standout
Update on cystic fibrosis-related diabetes
2013
Synthesis of New DPP-4 Inhibitors Based on a Novel Tricyclic Scaffold
2015
No Strict Correlation Between Necrosis and Organ Failure in Acute Pancreatitis
2000
Quest for a COVID-19 Cure by Repurposing Small-Molecule Drugs: Mechanism of Action, Clinical Development, Synthesis at Scale, and Outlook for Supply
2020
Temperature independent drift mobility along the molecular direction ofAs 2 S 3
1977
Reduced Postprandial Concentrations of Intact Biologically Active Glucagon-Like Peptide 1 in Type 2 Diabetic Patients
2001
Twenty-four-hour insulin secretion rates, circulating concentrations of fuel substrates and gut incretin hormones in healthy offspring of Type II (non-insulin-dependent) diabetic parents: evidence of several aberrations
1999
Incretin Levels and Effect Are Markedly Enhanced 1 Month After Roux-en-Y Gastric Bypass Surgery in Obese Patients With Type 2 Diabetes
2007
Incretin Effects of Increasing Glucose Loads in Man Calculated from Venous Insulin and C-Peptide Responses*
1986
Multiple tachykinins are produced and secreted upon post-translational processing of the three substance P precursor proteins, α-, β-, and γ-preprotachykinin
1989 StandoutNobel
Radiolabeled Somatostatin Analog [177Lu-DOTA0,Tyr3]Octreotate in Patients With Endocrine Gastroenteropancreatic Tumors
2005
Mechanisms of Recovery From Type 2 Diabetes After Malabsorptive Bariatric Surgery
2006
Therapeutic Strategies Based on Glucagon-Like Peptide 1
2004
Mobilities In Organic Molecular Crystals
1982
Mechanisms of Diabetic Complications
2013 Standout
Incretins and the development of type 2 diabetes
2006
Applications of Modern Ferroelectrics
2007 StandoutScience
Gluco-incretins control insulin secretion at multiple levels as revealed in mice lacking GLP-1 and GIP receptors
2004
The Glucagon-Like Peptides
1999
Reduced Insulinotropic Effect of Gastric Inhibitory Polypeptide in First-Degree Relatives of Patients With Type 2 Diabetes
2001
New Drugs for the Treatment of Diabetes
2008
The glucose dependent insulinotropic polypeptide response to oral glucose and mixed meals is increased in patients with Type 2 (non-insulin-dependent) diabetes mellitus
1989
The polyprotein nature of substance P precursors
1989
The hypocretins: Hypothalamus-specific peptides with neuroexcitatory activity
1998 Standout
One Hundred Years After “Carcinoid”: Epidemiology of and Prognostic Factors for Neuroendocrine Tumors in 35,825 Cases in the United States
2008 Standout
Cloning and Functional Expression of the Human Islet GLP-1 Receptor: Demonstration That Exendin-4 Is an Agonist and Exendin-(9–39) an Antagonist of the Receptor
1993
The Pathophysiology of Diabetes Involves a Defective Amplification of the Late-Phase Insulin Response to Glucose by Glucose-Dependent Insulinotropic Polypeptide—Regardless of Etiology and Phenotype
2003
Defective amplification of the late phase insulin response to glucose by GIP in obese Type II diabetic patients
2002
Imaging Schottky Barriers and Ohmic Contacts in PbS Quantum Dot Devices
2012 StandoutNobel
Incretin therapies: highlighting common features and differences in the modes of action of glucagon‐like peptide‐1 receptor agonists and dipeptidyl peptidase‐4 inhibitors
2015
Studies of Organic Semiconductors for 40 Years—III
1989
Isolation and characterization of neurokinin A, neurokinin A(3–10) and neurokinin A(4–10) from a neutral water extract of a metastatic ileal carcinoid tumour
1987
Neuropeptide K potently stimulates salivary gland secretion and potentiates substance P-induced salivation.
1989
Schottky barriers to colloidal quantum dot films
2007
Works of F. Stöckmann being referenced
On the Role of Gastrin-Releasing Peptide in Meal-Stimulated Exocrine Pancreatic Secretion
1999
Treatment of Gastrointestinal Endocrine Tumours with Interferon-α and Octreotide
1991
Influence of a platelet-activating factor antagonist on severe pancreatitis in two experimental models
1992
Etiology and Age Have Only a Limited Influence on the Course of Acute Pancreatitis
1996
IMPAIRMENT OF STIMULATED INSULIN RELEASE FROM THE ISOLATED PERFUSED RAT PANCREAS BY CYCLOSPORINE PRETREATMENT
1989
Gabexate mesilate in human acute pancreatitis
1993
CIRCULATING BRADYKININ‐LIKE IMMUNOREACTIVITY AND THE PENTAGASTRIN‐INDUCED CARCINOID FLUSH
1988
Quantitative Studies of Gastric Endocrine Cells in Patients Receiving Long-term Treatment with Omeprazole
1989
Detection of the Human Glucagon-Like Peptide 1(7-36) Amide Receptor on Insulinoma-Derived Cell Membranes
1994
Long-Term Omeprazole Treatment in Man: Effects on Gastric Endocrine Cell Populations
1988
Electron and Hole Mobilities in Solid and Liquid Benzene C6H6
1972
Treatment of metastasized midgut carcinoids with dacarbazine.
1995
Disturbances of the entero-insular axis.
1983
Hepatic artery embolization for treatment of endocrine gastrointestinal tumors with liver metastases.
1984
Reduced incretin effect in Type 2 (non-insulin-dependent) diabetes
1986
Carcinoids and carcinoid syndrome
1987
Photodetectors, their performance and their limitations
1975
Measurement and partial characterization of the multiple forms of neurokinin A-like immunoreactivity in carcinoid tumours
1986
Raumladungsbegrenzte Ströme in Halbleitern mit sperrenden Kontakten
1963
Serotonin release into blood after food and pentagastrin
1986
Preceding Hyperinsulinemia Prevents Demonstration of Insulin Effect on Fat-induced Gastric Inhibitory Polypeptide (GIP)
1984
Morbidity and mortality in 602 patients with acute pancreatitis seen between the years 1980-1994.
1996
Effect of a Specific Serine Protease Inhibitor on the Rat Pancreas: Systemic Administration of Camostate and Exocrine Pancreatic Secretion
1984